Posters
Minimally invasive glaucoma surgery: 5 years - results with the iStent injection
Poster Details
First Author: K.Klabe GERMANY
Co Author(s):
Abstract Details
Purpose:
A large number of minimally invasive micro-bypass systems have come onto the market in recent years. Given encouraging initial results, the question of a long-term sustainable effectst on the intraocular pressure reduction remains. In this context, we report on our 5-year results with the iStent inject from our practice.
Setting:
Internationale Innovative Ophthalmochirurgie Düsseldorf, Germany; International Vision Correction Research Network, Germany
Methods:
The iStent injection was used in on combination surgery with phacoemulsification for phakic patients. Another time we report on the stand-alone procedure for pseudophakic patients. We monitored the development of visual acuity, intraocular pressure and medication consumption in our patients. In addition, the complication rate and necessary further other glaucoma surgery were analyzed.
Results:
In the context of combined surgery, the intraocular pressure dropped significantly. A significant reduction in medication requirements was also achieved. After 5 years, we can have an average IOP drop of 21% and average drug use 0.19 instead of 1.47 preoperatively. As Complication we have 11 eyes with hyphema, 7 eyes with iStent occlusion and 2 eyes with hypotension and incarceration of the iris. With 5 eyes within 5 years, a new glaucoma operation was necessary.
Conclusions:
The iStent injection shows a good pressure-reducing effect in our patient population, which remains stable over a period of more than 5 years. This reduction in intraocular pressure is accompanied by a significant and sustained reduction in medication. With appropriate patient selection, the number of necessary second interventions is also very small.
In our experience, the iStent injection thus confirms the positive results even over a longer postoperative course (> 5 years).
Financial Disclosure:
None
